JP2705177B2 - Skin ulcer treatment - Google Patents
Skin ulcer treatmentInfo
- Publication number
- JP2705177B2 JP2705177B2 JP1003366A JP336689A JP2705177B2 JP 2705177 B2 JP2705177 B2 JP 2705177B2 JP 1003366 A JP1003366 A JP 1003366A JP 336689 A JP336689 A JP 336689A JP 2705177 B2 JP2705177 B2 JP 2705177B2
- Authority
- JP
- Japan
- Prior art keywords
- sugar
- skin ulcer
- skin
- ointment
- therapeutic agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
【発明の詳細な説明】 （産業上の利用分野） 本発明は，切傷，熱傷等の皮膚潰瘍の治療に使用され
る外用剤に関する。Description: TECHNICAL FIELD The present invention relates to an external preparation for use in treating skin ulcers such as cuts and burns.
（従来の技術） 従来，切傷，熱傷等の創傷治療においては，通常創傷
部位を先ず殺菌消毒した後，傷んだ部位の組織修復を図
る薬剤が使用される。2. Description of the Related Art Conventionally, in the treatment of wounds such as cuts and burns, an agent for sterilizing and disinfecting a wound site first and then repairing the tissue at the damaged site is used.
ポビドンヨード（ポリビニルピロリドン・ヨード錯
体）は，強力な殺菌作用を有し，皮膚の消毒剤，手術部
位の消毒剤などとして使用されているが，組織修復作用
は有していない。Povidone-iodine (polyvinylpyrrolidone-iodine complex) has a strong bactericidal action and is used as a disinfectant for skin and a disinfectant for surgical sites, but has no tissue repairing action.
ポビドンヨードに白糖を練合したものは，組織修復作
用を有し，皮膚潰瘍治療剤として効果があるとされてい
る〔曽根清和ら：病院薬学,10（５）,315−322（198
4）〕。Povidone-iodine kneaded with sucrose has a tissue-repairing effect and is said to be effective as a therapeutic agent for skin ulcers [Sone, S. et al .: Hospital Pharmacy, 10 (5), 315-322 (198)
Four)〕.
一方，塩化リゾチームは，線維芽細胞の増殖促進作
用，肉芽形成促進作用を主徴とし，さらに殺菌作用も有
するものとして，その軟膏剤が皮膚潰瘍治療薬として，
臨床的に使用され，効果が認められている。On the other hand, lysozyme chloride is mainly characterized by promoting proliferation of fibroblasts and promoting granulation, and also has a bactericidal effect.
Clinically used and effective.
（発明が解決しようとする課題） しかしながら，前記ポビドンヨードに糖を練合した薬
剤の組織修復作用はそれほど強力ではなく，塩化リゾチ
ームの殺菌作用は消毒剤として使用するほどには強力で
はない。(Problems to be Solved by the Invention) However, the drug obtained by kneading sugar with povidone iodine is not so powerful in tissue repair, and the bactericidal action of lysozyme chloride is not so strong as to be used as a disinfectant.
皮膚潰瘍の治療薬としては，常にその効果がより高い
ものが求められており，前記の塩化リゾチームを含む軟
膏剤またはポビドンヨードと糖を含む軟膏剤のような皮
膚潰瘍治療剤で充分ということはない。As a treatment for skin ulcers, a drug with a higher effect is always required, and a treatment for skin ulcers such as the ointment containing lysozyme chloride or the ointment containing povidone iodine and sugar is not sufficient. .
そこで，本発明は，従来のものよりさらに治療効果の
高い，皮膚潰瘍治療剤を提供しようとするものである。Then, this invention aims at providing the skin ulcer remedy which has a higher therapeutic effect than the conventional one.
（課題を解決するための手段） 本発明者らは，消毒と創傷治療を同時に行なわせる効
果をもつ治療剤について，鋭意研究の結果，塩化リゾチ
ーム，ポビドンヨードおよび糖を配合することにより，
塩化リゾチーム単独によるもの，またはポビドンヨード
および糖を含有するものに比較して，顕著な皮膚潰瘍治
療効果を示すことを見い出し，本発明を完成するに至つ
た。(Means for Solving the Problems) The present inventors have conducted intensive studies on a therapeutic agent having an effect of simultaneously performing disinfection and wound treatment, and as a result of blending lysozyme chloride, povidone iodine and sugar,
The present inventors have found that the present invention shows a remarkable therapeutic effect on skin ulcers as compared with lysozyme chloride alone or those containing povidone iodine and sugar, thereby completing the present invention.
すなわち，本発明は，塩化リゾチーム，ポビドンヨー
ドおよび糖を有効成分として含有してなる皮膚潰瘍治療
剤に関する。That is, the present invention relates to a therapeutic agent for skin ulcer comprising lysozyme chloride, povidone iodine and sugar as active ingredients.
本発明において，高い皮膚潰瘍治療効果を得るために
好ましい上記３成分の配合比としては，塩化リゾチー
ム：ポビドンヨード：糖が２〜8:1:10〜50（重量比）で
あり,4〜8:1:20〜40（重量比）とすることがより好まし
い。最も相乗効果の発現が高く，好ましいのは，約6:1:
約30（重量比）である。In the present invention, the preferable mixing ratio of the above three components to obtain a high skin ulcer treatment effect is lysozyme chloride: povidone iodine: sugar in a ratio of 2 to 8: 1: 10 to 50 (weight ratio), and 4 to 8: The ratio is more preferably 1:20 to 40 (weight ratio). The most synergistic effect is most pronounced, preferably about 6: 1:
It is about 30 (weight ratio).
上記の糖としては，白糖が効果が高く好ましい。 As the above sugar, sucrose is preferable because of its high effect.
本発明の皮膚潰瘍治療剤は，軟膏剤，貼布剤等の形態
で使用される。The therapeutic agent for skin ulcer of the present invention is used in the form of an ointment, a patch or the like.
軟膏剤とする際には，通常使用される基剤，安定剤，
湿潤剤，保存剤などが必要に応じて配合され，常法によ
り混合，製剤化される。When used as an ointment, commonly used bases, stabilizers,
Wetting agents, preservatives, and the like are mixed as necessary, and mixed and formulated by a conventional method.
基剤としては，流動パラフイン，白色ワセリン，サラ
シミツロウ，鯨ロウ，オクチルドデシルアルコール，パ
ラフインなどが使用される。As a base, liquid paraffin, white petrolatum, beeswax, spermaceti, octyldodecyl alcohol, paraffin and the like are used.
安定剤としては，ステアリン酸アルミニウム,D−マン
ニトールなどが使用される。As the stabilizer, aluminum stearate, D-mannitol and the like are used.
湿潤剤としては，ステアリルアルコール，セチルアル
コールなどが使用される。As the wetting agent, stearyl alcohol, cetyl alcohol and the like are used.
保存剤としては，パラオキシ安息香酸メチル，パラオ
キシ安息香酸エチル，パラオキシ安息香酸プロピルなど
が使用される。As the preservative, methyl paraoxybenzoate, ethyl paraoxybenzoate, propyl paraoxybenzoate and the like are used.
軟膏剤中の有効成分の量は，前記の塩化リゾチーム：
ポビドンヨード：糖の配合比であることが好ましい以
外，特に制限はないが，一般に，塩化リゾチーム１〜12
重量％，特に２〜５重量％，ポビドンヨード0.5〜1.5重
量％，糖５〜75重量％，特に10〜40重量％とされるのが
よい。The amount of the active ingredient in the ointment is determined by the lysozyme chloride described above:
There is no particular limitation except for the preferred ratio of povidone-iodine: sugar, but generally, lysozyme chloride 1 to 12 is used.
% By weight, especially 2 to 5% by weight, 0.5 to 1.5% by weight of povidone iodine, 5 to 75% by weight of sugar, especially 10 to 40% by weight.
得られる軟膏剤は，切傷，熱傷などの皮膚潰瘍患者に
使用されるが，使用量及び使用頻度は，病巣の広さ，状
態に応じ，適宜選択される。The resulting ointment is used for patients with cutaneous ulcers such as cuts and burns. The amount and frequency of use are appropriately selected according to the size and condition of the lesion.
（実施例） （１） 軟膏剤の製造 本実施例では，有効成分として塩化リゾチームを50mg
（力価）/g含有するリフラツプ軟膏（日立化成工業
（株）製，皮膚潰瘍治療剤）と，有効成分としてポビド
ンヨードを10重量％含有するイソジンゲル（明治製菓
（株）製，消毒剤）を使用した。(Example) (1) Production of ointment In this example, 50 mg of lysozyme chloride was used as an active ingredient.
(Potency) / g riflap ointment (manufactured by Hitachi Chemical Co., Ltd., skin ulcer treatment) and isodine gel containing 10% by weight of povidone iodine (Meiji Seika Co., Ltd., antiseptic) did.
まず，イソジンゲル90重量部，白糖200重量部及び単
シロツプ（白糖850gを水に溶かして1000mlとした液）60
重量部を練合した（以下，これをイソジンシユガーゲル
とする）。First, 90 parts by weight of isodine gel, 200 parts by weight of sucrose, and a single syrup (850 g of sucrose dissolved in water to make 1000 ml) 60
Parts by weight were kneaded (hereinafter, this is referred to as isosin shugar gel).
次いで，リフラツプ軟膏と，イソジンシユガーゲル又
はイソジンゲルとを表１に示す用量で乳鉢に取り，乳棒
でよくかきまぜて配合し，軟膏剤，，およびを
得た。Next, the reflat ointment and the isodine gel or the isodine gel were taken in a mortar at the doses shown in Table 1 and mixed well with a pestle to obtain an ointment.
（２） ラツトにおける切創の治療効果 ラツトの背部被毛をバリカン及び除毛剤で除去した。
皮膚の刺激が治まつた翌日，ペントバルビタールで麻酔
したラツトを腹位に固定し，正中線に直角に鋭利なカミ
ソリで皮膚を3cm切開した。そして，その中央部を１カ
所手術用縫合系で縫合した。前項で調製した軟膏剤，
及び対照物質を１日１回５日間,0.3gを毎日塗布し
た。５日目に縫合した手術用縫合糸を抜糸し,6日目に放
血致死させ，切創部を含む皮膚を一定面積剥離し，レオ
メータに装着した。レオメータを5c/minの速さで引つ張
り，切創部が開口するに要する力を加重（g:グラム）で
表わした。 (2) Therapeutic effect of cut wound on rat The back coat of the rat was removed with a hair clipper and a hair remover.
The day after the skin irritation subsided, a rat anesthetized with pentobarbital was fixed in the abdominal position, and a 3 cm incision was made on the skin with a sharp razor perpendicular to the midline. Then, the central part thereof was sutured at one place with a surgical suture system. Ointment prepared in the previous section,
0.3 g of the control substance was applied daily for 5 days once a day. The surgical suture that had been sutured on the 5th day was removed, and the blood was killed by exsanguination on the 6th day. The rheometer was pulled at a speed of 5 c / min, and the force required to open the incision was expressed in terms of weight (g: grams).
その結果を表２に示した。 The results are shown in Table 2.
（３） ラツトにおける熱傷の治療効果 ラツトの背部被毛をバリカン及び除毛剤で除去した。
皮膚の刺激が治まつた翌日，ペントバルビタールで麻酔
したラツトを腹位に固定し，正中線をはさんだ直角の位
置２カ所に軽度の３度熱傷を作製した。前項で調製した
軟膏剤〜及び対照物質を１日１回28日間,0.3gを毎
日塗布した。熱傷作製７日目に写真撮影し，その熱傷の
面積をデジタイザーで測定した。 (3) Therapeutic Effect of Burn on Rats The back hair of the rat was removed with a hair clipper and a hair remover.
The day after the skin irritation subsided, a rat anesthetized with pentobarbital was fixed in the abdominal position, and mild third-degree burns were made at two positions perpendicular to the midline. 0.3 g of the ointment prepared in the previous section and the control substance were applied once daily for 28 days. Photographs were taken on the 7th day of burn generation, and the area of the burn was measured with a digitizer.
その結果を表3,表４に示した。 The results are shown in Tables 3 and 4.
なお，表３の実験と表４の実験では，熱傷の作製条件
に相違があるため，熱傷面積に相違が生じている。Note that there is a difference in the burn area between the experiment in Table 3 and the experiment in Table 4 because the burn conditions are different.
以上の結果から，皮膚潰瘍に対して，塩化リゾチー
ム，ポビドンヨード及び糖の３成分の相乗効果が明確に
認められる。 From the above results, a synergistic effect of the three components of lysozyme chloride, povidone-iodine and sugar on skin ulcers is clearly recognized.
（発明の効果） 本発明に係る皮膚潰瘍治療剤は，高い創傷治癒効果を
示す。(Effect of the Invention) The therapeutic agent for skin ulcer according to the present invention exhibits a high wound healing effect.
───────────────────────────────────────────────────── フロントページの続き (72)発明者 向尾 正昭 東京都新宿区西新宿２丁目１番１号 日 立化成工業株式会社内 (56)参考文献 特開 昭60−149531（ＪＰ，Ａ) 特開 昭55−141409（ＪＰ，Ａ) ──────────────────────────────────────────────────続 き Continuation of front page (72) Inventor Masaaki Mukai 2-1-1 Nishi Shinjuku, Shinjuku-ku, Tokyo Inside Hitachi Chemical Co., Ltd. (56) References JP-A-60-149513 (JP, A) JP-A-55-141409 (JP, A)
Claims (4)
を有効成分として含有してなる皮膚潰瘍治療剤。1. A therapeutic agent for skin ulcer comprising lysozyme chloride, povidone iodine and sugar as active ingredients.
療剤。2. The therapeutic agent for skin tumor according to claim 1, wherein the sugar is sucrose.
ビドンヨード：糖で２〜8:1:10〜50である請求項１又は
２記載の皮膚潰瘍治療剤。3. The therapeutic agent for skin ulcer according to claim 1, wherein the weight ratio of the active ingredient is lysozyme chloride: povidone iodine: sugar from 2 to 8: 1: 10 to 50.
潰瘍治療剤。4. The therapeutic agent for skin ulcer according to claim 1, which is an ointment.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP1003366A JP2705177B2 (en) | 1989-01-10 | 1989-01-10 | Skin ulcer treatment |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP1003366A JP2705177B2 (en) | 1989-01-10 | 1989-01-10 | Skin ulcer treatment |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH02184634A JPH02184634A (en) | 1990-07-19 |
| JP2705177B2 true JP2705177B2 (en) | 1998-01-26 |
Family
ID=11555346
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP1003366A Expired - Fee Related JP2705177B2 (en) | 1989-01-10 | 1989-01-10 | Skin ulcer treatment |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP2705177B2 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH04145019A (en) * | 1990-10-02 | 1992-05-19 | Dia Seiyaku Kk | Poultice containing lysozyme chloride |
| CN105963689A (en) * | 2016-05-11 | 2016-09-28 | 山东司邦得制药有限公司 | Compound hydrochloric acid lysozyme ointment and preparation method and application thereof |
-
1989
- 1989-01-10 JP JP1003366A patent/JP2705177B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JPH02184634A (en) | 1990-07-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR890001881B1 (en) | Composition of cream base | |
| JP4987209B2 (en) | Use of biguanide derivatives for the manufacture of pharmaceuticals with scarring action | |
| JPH09510978A (en) | Starch-metal complex for skin and hair | |
| JP2705177B2 (en) | Skin ulcer treatment | |
| JP3899267B2 (en) | Use of tosylchloramide to treat skin, mucous membrane, organ or tissue disorders | |
| JP2640597B2 (en) | Wound healing promoter | |
| JPH08259464A (en) | Local anesthetic composition | |
| CA1222455A (en) | Agent for the treatment of wounds | |
| JP3524169B2 (en) | Skin cosmetics for acne improvement | |
| US4590212A (en) | Method of increasing the rate of wound healing and composition | |
| RU2740450C1 (en) | Dental gel with adaptogen for treating periodontal inflammatory diseases | |
| EP0367586B1 (en) | Primycin solutions | |
| KR0150641B1 (en) | Composition for local treatment of skin leishmaniasis and process for the preparation thereof | |
| RU2146922C1 (en) | Preparation for treatment of patient with trophic ulcers | |
| RU2122401C1 (en) | Wound-healing composition | |
| JP2004091386A (en) | Therapeutic agent for cutaneous ulcer for external use, kit for treating cutaneous ulcer and method for using extract of root of lithospermum radix | |
| JPH1149672A (en) | Plaster for wound treatment | |
| RU2160091C2 (en) | Wound healing agent | |
| RU2152205C1 (en) | Drug for treatment of patients with proctological diseases | |
| CN116528846A (en) | Formulations for healing of traumatic lesions of the skin and mucous membranes | |
| JP2001187741A (en) | Skin care medicinal composition | |
| RU2153352C1 (en) | Pharmaceutical composition showing wound-healing and anti-inflammatory effect | |
| EP1700597B1 (en) | Pharmaceutical composition containing in association ubidecarenone, dexpanthenol and chlorhexidine or a pharmaceutically acceptable salt thereof for cutaneous application | |
| JPH07215894A (en) | Wound-healing agent | |
| JPH0489427A (en) | External preparation for treating decubitus and skin ulcer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |